LEO Pharma Standardizes on Veeva Development Cloud to Speed Drug Development
Veeva Systems (NYSE:VEEV) today announced that LEO Pharma, a global leader in medical dermatology, selected Veeva Development Cloud applications to help drive end-to-end business processes across product development. The company will utilize the Vault Clinical, Vault RIM, and Vault Quality suites to unify drug development on a single cloud platform. With Veeva Development Cloud, LEO Pharma can bring together applications for clinical, regulatory, and quality for even greater efficiency and compliance throughout the product development lifecycle.
“LEO Pharma R&D has embarked on an ambitious strategy for 2025, which will pave the way for our ambitions to continuously pioneer dermatology. This requires that we are able to drive science globally, whilst at the same time securing timely delivery on our pipeline,” said Kim Kjøller, executive vice president of global research and development at LEO Pharma. “Veeva Development Cloud gives us a unified platform that can enable us to maximize efficiency throughout product development and scale as we grow towards our goals. Now we will be able to streamline product development globally and speed up delivery of new treatments to even more patients.”
LEO Pharma aims to reach 125 million patients who have chronic and acute skin conditions by 2025. To expand its drug development efforts, the company has made a number of significant acquisitions and established hubs in the United States and China. Veeva Development Cloud gives LEO Pharma’s global teams a single source for product development information to better maintain compliance and improve global collaboration.
“Veeva is helping us transform our entire R&D business,” said Mika Välilä, senior director of digital business platforms, global IT, for LEO Pharma. “Veeva Development Cloud allows us to drive greater consistency and productivity across product development efforts in clinical trials, regulatory matters, and quality.”
LEO Pharma today utilizes Vault eTMF, Vault Submissions, and Vault QualityDocs. In 2019, the company will add Vault CTMS, Vault Study Startup, Vault Registrations, and Vault QMS to further streamline the product development lifecycle across regions and departments.
“LEO Pharma is a great example of how organizations are modernizing critical business functions,” said Rik Van Mol, vice president of Veeva Development Cloud Strategy, Europe at Veeva. “Veeva Development Cloud gives life sciences companies the foundation to eliminate system, site, and country silos throughout drug development.”
Hear LEO Pharma and other customers discuss why they are standardizing on Veeva Development Cloud at the upcoming Veeva R&D Summit, Europe, June 11-13, 2019, Barcelona, Spain. See the agenda and register at veeva.com/eu/events/rd-summit.
For more on Veeva Development Cloud, visit: veeva.com/development-cloud
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies, and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million. For more information, go to www.linkedin.com/company/leo-pharma or www.leo-pharma.com.
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 700 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Avioq Announces CE Mark and European Launch of VioOne HIV Profile Supplemental Assay24.6.2019 15:11:00 CEST | Pressemelding
Avioq, Inc. has received CE Marking (Conformité Européenne) and has begun marketing their VioOne™ HIV Profile™ Supplemental Assay in the European Union and other CE Mark countries. The product has also been submitted for FDA approval. “We are pleased to provide the CE Mark HIV Profile™ assay to countries outside the U.S.,” said Chamroen Chetty, CEO of Avioq. Dr. Chetty continues, “We are also looking for distribution partners to expand the global availability.” The HIV Profile™ is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of HIV-1 (Group M & Group O) and HIV-2 in human serum or plasma that were repeatedly reactive in diagnostic screening procedures. Results can also be used to distinguish recent from longstanding HIV-1 infection for HIV-1 incidence estimation. About Confirmatory Testing In 2014, the CDC released a new algorithm for HIV testing. The second step of the algorithm includes a
Global Launch of S BLOCK, Kicked Off in Singapore on June 22nd24.6.2019 12:29:00 CEST | Pressemelding
The globally renowned 2019 WBF Singapore Technology Conference was held in Marina Bay Sands Hotel on June 22nd, 2019. S BLOCK, the conference co-host, unveiled itself and announce its mission to “Unleash your digital assets” for the first time. The conference brought together numerous industry elites and blockchain enthusiasts from all around the world, including more than 500 industry veterans from over 30 countries, such as Switzerland, Germany, France, Russia, Japan, Korea, Brazil, Australia, Argentina and Canada. Insiders shared profound global industry insights. This conference draws great attention from across the global blockchain industry. S BLOCK Kicked Off in Singapore In the morning of June 22nd, Ivan - President of S BLOCK Global Foundation, was invited to deliver a keynote speech, “Next Generation Digital Currency Wallet”. At this conference, S BLOCK was officially launched in more than 30 countries around the world, and opened up the way to a global future without borders
SpeeDx announce a collaborative agreement with GSK to supply tests and technology24.6.2019 12:00:00 CEST | Pressemelding
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to support certain GSK antibiotic clinical trials and new product development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005302/en/ “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impacting cure rates and helping to minimise the spread of antimicrobial resistant infections.” Colin Denver, SpeeDx CEO. (Photo: Business Wire) “We welcome this extension of the utility and application of our tests and technology,” said Colin Denver, SpeeDx CEO. “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impac
Nexon Computer Museum to Hold the Fourth VR Content Contest24.6.2019 10:13:00 CEST | Pressemelding
Nexon Computer Museum (NCM) of NXC is holding the fourth virtual reality content contest, ‘2019 NCM OPEN CALL X REALITY’. NXC is a holding company of Nexon (TOKYO: 3659). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005284/en/ Nexon Computer Museum (NCM) of NXC is holding the fourth virtual reality content contest 2019 NCM OPEN CALL X REALITY with total prize money of KRW 13 million. Application received from July 1st to August 31st, winners announced on October 25th. (Graphic: Business Wire) NCM OPEN CALL is an exhibit to discover and support virtual reality content creators. This year’s keyword ‘X REALITY’ encompasses all kinds of virtualization including VR, AR, MR, and more. It also implies eXtended Reality, which broadens the perspectives of reality, and Cross Reality, which overlaps the real and virtual world. The unpredictable X signifies NCM OPEN CALL’s pursuit towards embracing various kinds of innovative an
REPLY: New Tool “China Beats” Provides Deep Insights Into the Chinese Market24.6.2019 09:15:00 CEST | Pressemelding
TD Reply, the company specializing in marketing and innovation consulting within the Reply Group, developed China Beats, a business intelligence solution that enables companies to gain an in-depth understanding of the Chinese market and its players. This is ensured by AI-supported social listening with connection to all major Chinese e-commerce, social media and search platforms such as Alibaba, Baidu, WeChat and Weibo. The prosperity of the Chinese population is growing at a rapid pace. According to analysts estimates, around 550 million Chinese will belong to the middle class by 2022. As a result, the Chinese market is also becoming increasingly important for international companies. Entering the market, however, is challenging, especially in terms of reliable identification of target groups, analysis of their consumer behavior and preferences. Digital data can provide a remedy, because the majority of Chinese consumers are netizens who shop on digital platforms, exchange their opini
MYbank Works With Financial Institution Partners to Serve Over 15 Million SMEs24.6.2019 05:42:00 CEST | Pressemelding
MYbank, a leading online private commercial bank in China with a focus on SME financing, today announced that the bank’s Star Plan has enabled MYbank, with its financial institution partners, to serve over 15 million small and micro enterprises (SMEs). SMEs are key drivers of economic growth and this partnership is now serving more SMEs than any other in the world. The announcement comes on the day that MYbank celebrates its 4th Anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190623005055/en/ MYbank’s 310 lending model enables inclusive finance for SMEs in China (Photo: Business Wire) MYbank’s Star Plan was announced on June 21, 2018 with the aim of using technology to enable 1,000 financial institution partners to provide more cost-effective financing services to 30 million SMEs in China within a three-year period. A little over a year later and the Star Plan is showing significant progress. As of June 2019, lev